HEPATOPROTECTIVE EFFECT OF THE C23-DERIVATIVE OF THE URSODEOXYCHOLIC ACID IN EXPERIMENTAL NONALCOHOLIC STEATOHEPATITIS OF RATS
Abstract
The effects of the C23-derivative of ursodeoxycholic acid (nor-UDCA) in rats with nonalcoholic steatohepatitis (NASH) were studied. NASH was induced by the feeding of a liquid high-fat diet of Lieber-DeCarli for 16 weeks. Rats were daily administered with the derivative of UDCA in a dose of 38.6 mg/kg (equimolar to 40 mg/kg UDCA) by oral gavage for the last 4 weeks. Our study demonstrated that the treatment with nor-UDCA improved the liver steatosis and decreased the inflammation and the NASH-induced lipid peroxidation. The obtained experimental data allow us to make a conclusion that the derivative of UDCA in the same extent with UDCA possessed hepatoprotective properties but it has a more antioxidant potential than a mother compound.
About the Authors
E. B. BELONOVSKAYA
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
O. Y. LUKIVSKAYA
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
E. E. NARUTA
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
S. N. KIRKO
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
V. Z. ABAKUMOV
Grodno State Medical University
Belarus
Belarus
I. A. KUZMITSKAYA
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
V. U. BUKO
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus
Belarus
Belarus
References
1. A position statement on NAFLD/NASH based on the EASL 2009 special conference / V. Ratziu [et al.] // J. Hepatol. – 2010. – Vol. 53, N 2. – P. 372–384.
2. Serum markers of liver fibrosis in patients with non-alcocholic steatohepatitis (NASH). Correlation to morphology and effect of therapy / J. Holoman [et al.] // J. Hepatol. – 2000. – Vol. 32. – Р. 210.
3. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2–/– mice / E. Halilbasic [et al.] // J. Hepatol. – 2009. – Vol. 49. – P. 1972–1981.
4. Protective effects of norursodeoxycholic acid versus ursodeoxycholic acid on thioacetamide-induced rat liver fibrosis / V. Buko [et al.] // J. Clin. Exp. Hepatol. – 2014. – Vol. 4, N 4. – P. 293–301.
5. Model of nonalcoholic steatohepatitis / C. S. Lieber [et al.] // Am. J. Clin. Nutr. – 2004. – Vol. 79. – P. 502–509.
6. The autooxidation of human red cells lipids induced by hydrogen peroxide / J. Stocks [et al.] // Br. J. Haematol. – 1971. – Vol. 20, N 1. – P. 95–111.
7. A new and rapid colorimetric determination of acetylcholinesteraze activity / G. L. Ellman [et al.] // Biochem. Pharmacol. – 1961. – Vol. 7. – P. 88–95.
8. A sensitive microassay for the determination of glutathione peroxidase activity. Application to human blood platelets / J. I. R. Martinez [et al.] // Anal. Biochem. – 1979. – Vol. 98. – P. 154–159.
9. Effect of riboflavin depletion and repletion on the erythrocyte glutathione reductase in the rat / J. A. Tilbotson [et al.] // J. Nutrition. – 1971. – Vol. 101. – P. 1459–1466.
10. The amplified chemiluminescence test to characterize antirheumatic drugs as oxygen radical scavengers / R. Müller- Peddinhaus [et al.] // Biochem. Pharmacol. – 1987. – Vol. 36. – P. 1125–1132.
11. Nonsuperoxide lucigenin-enhanced chemiluminescence from phospholipids and human saphenous veins / D. A. Barber [et al.] // Free Radic. Biol. Med. – 1995. – Vol. 18, N 3. – P. 565–569.
12. Профилактическое применение новых производных урсодезоксихолевой кислоты при экспериментальном алкогольном стеатогепатите / Е. Б. Белоновская [и др.] // Эксперим. и клин. фармакология. – 2013. – Т. 76, № 1. – С. 25–29.
13. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis / N. Beraza [et al.] // Gut. – 2011. – Vol. 60. – P. 387–396.
14. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans / A. F. Hofmann [et al.] // Hepatology. – 2005. – Vol. 42. – P. 1391–1398.
15. Differing effect of nor-ursodeoxycholic and ursodeoxycholic acid on hepatic histology and bile acid metabolism in rabbit / B. I. Cohen [et al.] // Gastroenterology. – 1986. – Vol. 91. – P. 189–197.
16. 24-nor-ursodeoxycholic acid as novel therapeutic strategy for inflammation-induced liver fibrosis in a murine model of Shisostoma mansoni infection / M. Sombetzky [et al.] // J. Hepatol. – 2008. – Vol. 48, N 2. – P. 21–22.
Review
For citations:
BELONOVSKAYA E.B., LUKIVSKAYA O.Y., NARUTA E.E., KIRKO S.N., ABAKUMOV V.Z., KUZMITSKAYA I.A., BUKO V.U. HEPATOPROTECTIVE EFFECT OF THE C23-DERIVATIVE OF THE URSODEOXYCHOLIC ACID IN EXPERIMENTAL NONALCOHOLIC STEATOHEPATITIS OF RATS. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2016;(3):80-85. (In Russ.)
Views: 457
Email this article 